TCGX

Develops an oral AKT inhibitor for hereditary hemorrhagic telangiectasia

Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD

Develops first- and best-in-class antibody-drug conjugates (ADCs) for cancer treatment

Develops novel therapies to reduce the burden of neurodegenerative diseases

Develops next-generation therapies for immune-mediated inflammatory and fibrotic diseases